CTLA-4, LAG-3, TIGIT & Other Checkpoints

Cat. No.

A53628

CAS No.

3042848-87-0

Risvutatug

Synonyms: HS-20093 Antibody; GSK5764227 Antibody

Risvutatug is an anti-B7-H3 antibody designed to target the B7-H3 protein, a key player in immune regulation and tumor progression. This antibody exhibits potent anti-tumor activity and is valuable for studying various malignancies, including small cell lung cancer, relapsed or refractory osteosarcoma, and advanced solid tumors. Its application in the development of antibody-drug conjugates (ADCs) allows for targeted therapeutic strategies in cancer research.

Cat. No.

A64166

CAS No.

3042847-92-4

Mocertatug

Synonyms: GSK5733584 antibody; HS-20089 antibody; hu2F7

Mocertatug is a humanized IgG1κ antibody that specifically targets B7-H4/VTCN1, a co-inhibitory molecule involved in immune regulation. This antibody is designed for applications in antibody-drug conjugate (ADC) development, including the construction of Mocertatug Rezetecan. Its utilization in research may provide insights into tumor immunity and potential therapeutic strategies for cancer treatment.

Cat. No.

A64571

CAS No.

3014361-57-7

Futermestotug

Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody that specifically targets human cytotoxic T-lymphocyte associated protein 4 (CTLA4). This compound is primarily utilized in research focused on various malignant tumors, facilitating the study of immune modulation and potential therapeutic interventions in oncology. Its ability to engage the CTLA4 pathway makes it a valuable tool for elucidating mechanisms of immune evasion in cancer.

Cat. No.

A64835

CAS No.

3036192-53-4

Zamristobart

Synonyms: SAR-444881

Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody designed to modulate immune responses. This antibody exhibits immunostimulant and antineoplastic activities, making it a valuable tool for research in cancer immunotherapy and immune regulation studies. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control.

Cat. No.

AT0018

CAS No.

2044984-83-8

Etigilimab

Synonyms: OMP-313M32

Etigilimab is a humanized IgG1 monoclonal antibody that blocks the interaction between TIGIT and its ligand CD155 (PVR), a key pathway in immune checkpoint regulation. By inhibiting TIGIT signaling, Etigilimab enhances T cell–mediated immune responses and is widely used in tumor immunology research and checkpoint blockade studies.

Cat. No.

AT0080

CAS No.

2254059-25-9

Quavonlimab

Synonyms: MK-1308

Quavonlimab (MK-1308) represents a novel monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This therapeutic agent is designed to modulate immune responses by inhibiting CTLA-4, a protein that plays a crucial role in regulating immune checkpoints. Quavonlimab is primarily utilized in research focusing on immune-oncology and the potential enhancement of anti-tumor immunity.

Cat. No.

AT0104

CAS No.

2888563-73-1

Alcestobart

Alcestobart is a human monoclonal antibody of the IgG4κ subtype that specifically targets LAG3. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This pairing ensures accurate assessment of target specificity and antibody performance in research applications.

Cat. No.

AT0130

CAS No.

2640981-19-5

Polzastobart

Synonyms: JTX 8064

Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody that functions as an antagonist by selectively targeting and binding to LILRB2. This interaction inhibits LILRB2 from associating with its natural ligands, including both classical and non-classical MHC class I molecules. By preventing LILRB2 from binding to HLA-A/B and HLA-G, which are markers of immunotolerance on tumor cells, Polzastobart effectively disrupts this inhibitory signal and enhances the production of pro-inflammatory cytokines in macrophages. This mechanism classifies Polzastobart as a macrophage immune checkpoint inhibitor, making it a critical tool in cancer immunotherapy research.

Cat. No.

AT0134

CAS No.

2411914-36-6

Tamgiblimab

Synonyms: IBI939

Tamgiblimab (IBI939) is a fully human monoclonal antibody that specifically targets the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). This antibody exhibits potent anticancer properties by modulating immune system responses, potentially enhancing the recognition and destruction of cancer cells. Tamgiblimab is designed for therapeutic applications in oncology, focusing on harnessing the body's immune system to combat various malignancies.

Cat. No.

AT0146

CAS No.

2643331-31-9

Perenostobart

Synonyms: SRF617

Perenostobart is a humanized monoclonal antibody of the immunoglobulin G4-kappa subclass, specifically targeting ENTPD1/CD39. This antibody functions as an immunostimulant and possesses antineoplastic properties, making it a valuable tool in cancer immunotherapy research. Its selective binding to ENTPD1/CD39, an enzyme involved in the hydrolysis of extracellular nucleotides, modulates immune responses and potentially disrupts tumor-promoting mechanisms. Perenostobart is applicable in studies focused on the regulation of immune checkpoints and the tumor microenvironment.

Cat. No.

AT0153

CAS No.

2137049-37-5

Ieramilimab

Synonyms: LAG525; IMP701

Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody designed to target and bind to lymphocyte-activation gene 3 (LAG-3). This interaction effectively inhibits the binding of LAG-3 to major histocompatibility complex class II (MHC-II) molecules, which is critical in modulating immune response. Ieramilimab is utilized extensively in research focused on immune checkpoint regulation and potential therapeutic interventions for various immunological disorders.

Cat. No.

AT0162

Anti-PVRIG Antibody (COM701)

Synonyms: COM701

The Anti-PVRIG Antibody (COM701) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the PVRIG protein. This antibody has a predicted molecular weight of 145.48 kDa. It is of the human IgG4 kappa isotype, and suitable isotype controls are available for experimental validation. This product is ideal for use in research focused on the role of PVRIG in immune modulation and cancer immunotherapy.

Cat. No.

AT0186

CAS No.

2378407-27-1

Uliledlimab

Synonyms: TJ004309

Uliledlimab is a humanized monoclonal antibody that targets CD73, exhibiting potent inhibitory activity. This antibody effectively blocks the enzymatic conversion of extracellular adenosine monophosphate (AMP) to adenosine, a mechanism implicated in tumor evasion of immune surveillance. Uliledlimab is primarily utilized in cancer research, where it serves as a critical tool for studying the role of the adenosine pathway in tumor progression and response to therapy.

Cat. No.

AT0227

CAS No.

2236068-83-8

Tifcemalimab

Synonyms: JS004

Tifcemalimab (JS004) is a humanized monoclonal antibody that targets BTLA (B and T lymphocyte attenuator), a key regulator in the immune checkpoint pathway. By binding specifically to BTLA, Tifcemalimab effectively inhibits the interaction between BTLA and its ligand HVEM, thereby blocking the BTLA-mediated inhibitory signaling pathway. This antibody is primarily utilized in cancer research to study the modulation of immune responses against tumor cells.

Cat. No.

AT0235

CAS No.

1353485-38-7

Enoblituzumab

Synonyms: MGA271

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody designed to specifically target the human B7-H3 protein, which is part of the B7 family of immune regulators. This antibody has been engineered for high specificity and affinity in recognizing its antigen, making it suitable for research focused on immune regulation and potential therapeutic applications.

Cat. No.

AT0239

CAS No.

2342597-93-5

Ociperlimab

Synonyms: BGB-A1217

Ociperlimab is a humanized IgG1 monoclonal antibody targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT). It exhibits high-affinity binding to the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. By inhibiting the interaction between TIGIT and its ligands, poliovirus receptor (PVR) and PVR-like 2 (PVR-L2), Ociperlimab serves as a potent tool in the modulation of immune responses. This antibody is particularly useful in the research of cancer immunotherapy, facilitating the study of TIGIT as an immune checkpoint in various oncological models.

Cat. No.

AT0242

CAS No.

2254029-91-7

Alsevalimab

Alsevalimab is a human monoclonal antibody specifically designed to target and bind to the B7-H4 protein. This interaction plays a critical role in modulating immune responses, making Alsevalimab a valuable tool for research into immunological pathways and potential therapeutic applications in diseases where B7-H4 is implicated.

Cat. No.

AT0279

CAS No.

2855971-15-0

Emiltatug

Emiltatug is a human monoclonal antibody of the IgG1κ subtype that specifically targets VTCN1 (V-set domain-containing T-cell activation inhibitor 1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0284

CAS No.

2920425-39-2

Remzistotug

Remzistotug is a human monoclonal antibody of the IgG1κ subtype designed to specifically target PVRIG. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0292

CAS No.

2226344-78-9

Gotistobart

Synonyms: ONC-392; BNT 316

Gotistobart (ONC-392) is a humanized monoclonal antibody targeting CTLA-4, designed to enhance immunotherapeutic efficacy through the selective depletion of regulatory T cells (Tregs) within the tumor microenvironment. This antibody facilitates a targeted approach to modulate the immune system, potentially improving treatment outcomes in cancer immunotherapy.

Cat. No.

AT0305

CAS No.

2649372-91-6

Porustobart

Synonyms: HBM-4003

Porustobart is a monoclonal antibody specifically targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This antibody is designed for use in research studies to investigate the modulation of immune checkpoints, which are crucial for understanding immune system behavior in cancer and other diseases. Porustobart can be utilized in various experimental settings, including flow cytometry, Western blotting, and immunoprecipitation, making it a valuable tool for researchers focusing on immunology and oncology.

Cat. No.

AT0350

CAS No.

2252262-24-9

Sabatolimab

Synonyms: MBG453

Sabatolimab (MBG453) is a high-affinity, humanized IgG4 (S228P) monoclonal antibody designed to specifically target TIM-3, an inhibitory receptor involved in the regulation of both adaptive and innate immune responses. This antibody serves as a potential agent for immunosuppression, targeting TIM-3 expressed on various immune and myeloid cells. Sabatolimab's specificity and mechanism of action make it a valuable tool for research in immune regulation and potential therapeutic applications in diseases characterized by immune dysregulation.

Cat. No.

AT0357

Anti-CTLA-4/CD152 Antibody (BN13)

Anti-CTLA-4/CD152 Antibody (BN13) is a chimeric mouse IgG2a, κ antibody designed to target human CTLA-4/CD152. For isotype control, it is recommended to use Mouse IgG2a kappa, Isotype Control, ensuring specificity and consistency in antibody performance.

Cat. No.

AT0401

CAS No.

2760250-47-1

Puxitatug

Puxitatug is a monoclonal antibody of the immunoglobulin G1-κ class, specifically targeting the human VTCN1 protein, also known as V-set domain-containing T cell activation inhibitor 1, B7 family member H4, B7H4, and B7-H4. This antibody binds selectively to VTCN1, a negative regulator of T cell-mediated immune responses, making it a valuable tool for research in immunology and oncology.

Cat. No.

AT0416

CAS No.

2599198-80-6

Danvilostomig

Danvilostomig is a monoclonal antibody designed to target CTLA4 and PDCD1, key immune checkpoint proteins. This antibody is utilized in the study of immune checkpoint regulation and has potential applications in immunotherapy research, particularly in the context of cancer and autoimmune diseases. Danvilostomig's dual specificity allows for comprehensive investigation into the mechanisms of T-cell regulation and immune tolerance.